---
title: 'Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up
  of the Phase 3 GMMG ReLApsE Trial'
date: '2025-01-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39808798/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250115170812&v=2.18.0.post9+e462414
source: Blood
description: The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61)
  randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to
  lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles)
  re-induction, salvage high dose chemotherapy (sHDCT, melphalan 200mg/m2), autologous
  stem cell transplantation (ASCT) and LEN maintenance (10mg/day; transplant arm,
  n=139) versus continuous LEN/DEX (control arm, n=138). Ninety-four percent of patients
  had ...
disable_comments: true
---
The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose chemotherapy (sHDCT, melphalan 200mg/m2), autologous stem cell transplantation (ASCT) and LEN maintenance (10mg/day; transplant arm, n=139) versus continuous LEN/DEX (control arm, n=138). Ninety-four percent of patients had ...